CBT services during the COVID-19 pandemic:
The Center for Biomedical Testing would like to reassure our clients that we are continuing our main activities in drug development and FDA submission.
The health and safety of our staff and clients are paramount and therefore we have enacted full COVID-19 safety precautions. There are no health concerns for any of our employees at this time and we do not expect any disruption in our research execution.
Please contact us with any testing requirements and we will continue to accommodate your needs to the best of our ability.
If you have any questions or concerns regarding your current or upcoming project please contact us. We will be happy to provide all the information you need.
Thank you for your cooperation and for using our services.
CBT recently completed complete IND packages for 3 drugs which are now in clinical trials in the USA and Australia. The clinical trials are also supported by CBT analytical work and PK analysis.
CBT recently developed new methods for several viral antibody titers and cell-based neutralization assays in rabbit and monkey plasma and serum. In addition, a method for ADA measurement in dog plasma was developed and successfully implemented using the MSD platform in 2018.
CBT developed new highly sensitive non-invasive methods for calprotectin and lactoferrin evaluation in non-human primate feces and cytokine methods in mouse blood and feces as biomarkers of gastro-intestinal inflammation (including for infections, bowel irritation and acute radiation syndrome).
CBT developed and validated new highly sensitive multiplex cytokine assays in non-human primate, dog, minipig, mice, and human plasma using the MSD chemiluminescent platform.
Recent Publications: GI Markers
Older Publications: PDF . ( )